Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it ...
Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; ...
The company is looking to score an FDA nod for its investigational therapy that targets a molecule linked to Guillain-Barré ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback